In inflammatory bowel disease, the biologic is often the difference between remission and a flare cycle. So the month a patient spends waiting for a payer to approve it is not neutral time — it’s time the inflammation keeps going, frequently bridged with steroids no one wants them on.
Gastroenterology’s prior-authorization burden concentrates in that wait.
The numbers in IBD
Published studies have measured the delay directly:
- 30.5 days mean time to biologic approval across IBD; 39.7 days for Crohn’s disease vs 21.8 days for ulcerative colitis (Rao et al., J Natl Med Assoc 2024).
- A 14.1% increase in corticosteroid dependence at 90 days associated with the prior-authorization delay, from a pediatric IBD cohort (Constant et al., Pediatrics 2022).
- 83% of gastroenterologists have had a patient hospitalized because of an inability to obtain timely PA (Constant et al., Clin Gastroenterol Hepatol 2023 provider survey).
These ride on top of the burden every physician reports — 39 authorizations per week, around 13 hours lost to them, 93% saying PA delays care (AMA 2024). In IBD, that general friction becomes a month-long gap in disease control.
Why gastroenterology is different
- Biologics with step therapy. IBD biologics are high-cost specialty drugs, so payers require documented failures of earlier agents — extending the path to the drug that controls the disease.
- The steroid bridge. While the biologic auth is pending, patients are often kept on corticosteroids, which is exactly the dependence the data flags. The delay creates its own clinical problem.
- Recurring re-authorizations. Maintenance therapy must be re-authorized periodically; a lapse means a flare while the paperwork resets.
- Per-payer documentation. The same severity scores, endoscopy findings, and therapy history get reassembled in each payer’s format.
What it costs
The cost is both clinical and operational. Clinically: more steroid dependence, more flares, and the downstream care each flare generates. Operationally: staff hours assembling severity documentation and re-authorizations at roughly $10.81 per manually processed authorization (CAQH 2023), recurring across every IBD patient on maintenance therapy. A 39.7-day Crohn’s approval isn’t one event — it’s weeks of follow-up, faxes, and peer-to-peers for a treatment the gastroenterologist already chose.
How to cut the wait
The IBD authorization packet — diagnosis, severity, prior agents, endoscopic findings — is structured clinical documentation, which is precisely what software should assemble and match. Artificer Health:
- Builds the clinical packet from the record, including the step-therapy history payers ask for.
- Matches it to the payer’s IBD policy so the first submission meets that payer’s criteria.
- Tracks maintenance re-authorizations so therapy never lapses for an administrative reason — and the steroid bridge gets shorter or disappears.
Shortening a 30-day approval to a first-pass decision in minutes isn’t just an efficiency win. In IBD, it’s fewer weeks on steroids, faster control of the disease, and a practice that doesn’t lose patients to hospitalization while the paperwork grinds.
Sources: Rao V et al., J Natl Med Assoc 2024 (PMID 38036315, mean time-to-approval 30.5 days, Crohn’s 39.7 vs UC 21.8 days); Constant BD et al., Pediatrics 2022 (PMID 35190811, +14.1% corticosteroid dependence at 90 days, pediatric IBD cohort); Constant BD et al., Clin Gastroenterol Hepatol 2023 (S1542-3565(23)00506-2, provider survey, 83% hospitalization rate); AMA 2024 Prior Authorization Physician Survey; CAQH 2023 Index.